AGMAT

Summary

AGMAT (agmatinase (putative), HGNC:18407) is a protein-coding gene on chromosome 1p36.21, encoding Guanidino acid hydrolase, mitochondrial (Q9BSE5). Hydrolyzes linear guanidino acids to form urea and the corresponding amines.

Enables arginase activity; guanidinobutyrase activity; and guanidinopropionase activity. Predicted to be involved in putrescine biosynthetic process from arginine, via agmatine. Located in mitochondrion.

Source: NCBI Gene 79814 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 83 total — 2 likely-pathogenic
• MANE Select transcript: NM_024758

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18407
Approved symbol	AGMAT
Name	agmatinase (putative)
Location	1p36.21
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23384
Ensembl gene	ENSG00000116771
Ensembl biotype	protein_coding
OMIM	617887
Entrez	79814

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000375826, ENST00000909207, ENST00000930535, ENST00000930536

RefSeq mRNA: 1 — MANE Select: NM_024758 NM_024758

CCDS: CCDS160

Canonical transcript exons

ENST00000375826 — 7 exons

Exon	Start	End
ENSE00000544310	15583193	15583395
ENSE00000544313	15577685	15577864
ENSE00000750501	15574757	15574841
ENSE00000750536	15578859	15579054
ENSE00000750537	15580094	15580142
ENSE00001468508	15571699	15573724
ENSE00001468525	15584696	15585051

Expression profiles

Bgee: expression breadth ubiquitous, 199 present calls, max score 98.90.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5612 / max 194.6285, expressed in 690 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
10461	2.5612	690

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
renal glomerulus	UBERON:0000074	98.90	gold quality
nephron tubule	UBERON:0001231	98.75	gold quality
metanephric glomerulus	UBERON:0004736	98.70	gold quality
kidney epithelium	UBERON:0004819	98.63	gold quality
renal medulla	UBERON:0000362	98.41	gold quality
adult organism	UBERON:0007023	97.12	gold quality
buccal mucosa cell	CL:0002336	95.98	gold quality
adult mammalian kidney	UBERON:0000082	94.25	gold quality
jejunal mucosa	UBERON:0000399	93.76	gold quality
liver	UBERON:0002107	93.63	gold quality
kidney	UBERON:0002113	92.25	gold quality
vastus lateralis	UBERON:0001379	91.41	gold quality
colonic mucosa	UBERON:0000317	91.27	gold quality
mucosa of sigmoid colon	UBERON:0004993	90.73	gold quality
jejunum	UBERON:0002115	90.63	gold quality
right lobe of liver	UBERON:0001114	90.34	gold quality
quadriceps femoris	UBERON:0001377	89.83	gold quality
ileal mucosa	UBERON:0000331	88.93	gold quality
duodenum	UBERON:0002114	87.84	gold quality
cortex of kidney	UBERON:0001225	86.99	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	86.50	gold quality
metanephros	UBERON:0000081	85.93	gold quality
biceps brachii	UBERON:0001507	85.72	gold quality
parotid gland	UBERON:0001831	84.16	silver quality
skeletal muscle tissue	UBERON:0001134	83.86	gold quality
secondary oocyte	CL:0000655	83.42	gold quality
oocyte	CL:0000023	83.17	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	83.08	gold quality
hindlimb stylopod muscle	UBERON:0004252	82.86	gold quality
mucosa of transverse colon	UBERON:0004991	82.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.27

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

73 targeting AGMAT, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-2052	99.79	69.37	2031
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-7844-5P	99.55	68.56	1428
HSA-MIR-106A-3P	99.53	67.58	995

Literature-anchored findings (GeneRIF, showing 8)

• an alternative to ornithine decarboxylase for polyamine biosynthesis (PMID:11804860)
• Agmatinase is down-regulated in the clear cell type of renal cell carcinoma (PMID:14648699)
• X-ray crystallographic analysis of human agmatinase (PMID:16511187)
• Agmatinase activity was predominantly detected in neurons of rat and human brain. (PMID:20563878)
• This study demonistrated that increased expression of agmatinase in hippocampal interneurons of subjects with mood disorders. (PMID:21803059)
• Enzymes that are directly involved in the formation of urea are expressed in ocular tissues. (PMID:23740519)
• Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway. (PMID:31699997)
• miR151a5p promotes the proliferation and metastasis of colorectal carcinoma cells by targeting AGMAT. (PMID:36704851)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	agmat	ENSDARG00000059700
mus_musculus	Agmat	ENSMUSG00000040706
rattus_norvegicus	Agmat	ENSRNOG00000012315
caenorhabditis_elegans		WBGENE00020658

Paralogs (2): ARG2 (ENSG00000081181), ARG1 (ENSG00000118520)

Protein

Protein identifiers

Guanidino acid hydrolase, mitochondrial — Q9BSE5 (reviewed: Q9BSE5)

Alternative names: Arginase, mitochondrial, Guanidinobutyrase, mitochondrial, Guanidinopropionase, mitochondrial

All UniProt accessions (1): Q9BSE5

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes linear guanidino acids to form urea and the corresponding amines. Displays specificity for substrates having a negatively charged head group and short chains including taurocyamine, guanidino propanoic and butanoic acids. May protect cells by detoxifying potentially harmful amounts of guanidino acids. Metabolizes L-arginine with low efficiency.

Subcellular location. Mitochondrion.

Tissue specificity. Highly expressed in liver and kidney. Also found in skeletal muscle, fetal liver, brain, testis, skin and the gastrointestinal tract. Within brain, expression is higher in the cerebral cortex with lower levels in the medulla and spinal cord.

Pathway. Nitrogen metabolism; urea cycle; L-ornithine and urea from L-arginine: step 1/1.

Similarity. Belongs to the ureohydrolase superfamily. Arginase family.

RefSeq proteins (1): NP_079034* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR005925	Agmatinase-rel	Family
IPR006035	Ureohydrolase	Family
IPR020855	Ureohydrolase_Mn_BS	Binding_site
IPR023696	Ureohydrolase_dom_sf	Homologous_superfamily

Pfam: PF00491

Enzyme classification (BRENDA):

• EC 3.5.3.11 — agmatinase (BRENDA: 16 organisms, 4 substrates, 30 inhibitors, 39 Km, 33 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
AGMATINE	0.53–50.5	37

Catalyzed reactions (Rhea), 4 shown:

• 3-guanidinopropanoate + H2O = urea + beta-alanine (RHEA:16029)
• 4-guanidinobutanoate + H2O = urea + 4-aminobutanoate (RHEA:19501)
• L-arginine + H2O = urea + L-ornithine (RHEA:20569)
• taurocyamine + H2O = urea + taurine (RHEA:75931)

UniProt features (17 total): binding site 8, modified residue 3, sequence variant 2, transit peptide 1, chain 1, sequence conflict 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BSE5-F1	92.12	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 278; 162; 185; 185; 187; 189; 276; 276

Post-translational modifications (3): 193, 217, 217

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-351143	Agmatine biosynthesis

MSigDB gene sets: 114 (showing top): ZHAN_MULTIPLE_MYELOMA_MF_UP, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_GLUTAMINE_FAMILY_AMINO_ACID_METABOLIC_PROCESS, GOBP_POLYAMINE_METABOLIC_PROCESS, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_AMIDE_METABOLIC_PROCESS, ACEVEDO_LIVER_TUMOR_VS_NORMAL_ADJACENT_TISSUE_DN, GOBP_AMIDE_BIOSYNTHETIC_PROCESS, LEE_EARLY_T_LYMPHOCYTE_DN, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP, TIEN_INTESTINE_PROBIOTICS_24HR_UP, WONG_MITOCHONDRIA_GENE_MODULE, OSMAN_BLADDER_CANCER_DN

GO Biological Process (4): urea cycle (GO:0000050), obsolete putrescine biosynthetic process from arginine, via agmatine (GO:0033389), agmatine biosynthetic process (GO:0097055), arginine metabolic process (GO:0006525)

GO Molecular Function (8): arginase activity (GO:0004053), agmatinase activity (GO:0008783), metal ion binding (GO:0046872), guanidinobutyrase activity (GO:0047971), guanidinopropionase activity (GO:0047972), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidines (GO:0016813)

GO Cellular Component (1): mitochondrion (GO:0005739)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Metabolism of polyamines	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amidines	4
biosynthetic process	1
urea metabolic process	1
primary amino compound biosynthetic process	1
amino acid metabolic process	1
carboxylic acid metabolic process	1
cation binding	1
binding	1
catalytic activity	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2108 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
AGMAT	AZIN2	Q96A70	857
AGMAT	ODC1	P11926	779
AGMAT	SRM	P19623	715
AGMAT	SMS	P52788	710
AGMAT	ASS1	P00966	608
AGMAT	OAT	P04181	599
AGMAT	OTC	P00480	579
AGMAT	DOHH	Q9BU89	563
AGMAT	DHPS	P49366	544
AGMAT	PAOX	Q6QHF9	525
AGMAT	SMOX	Q9NWM0	523
AGMAT	ASL	P04424	519
AGMAT	AGXT2	Q9BYV1	502
AGMAT	SAT1	P21673	502
AGMAT	AMPD2	Q01433	502

IntAct

131 interactions, top by confidence:

A	B	Type	Score
YIPF1	YIPF6	psi-mi:“MI:0914”(association)	0.840
DPF3	ARID1A	psi-mi:“MI:0914”(association)	0.530
PURG	U2SURP	psi-mi:“MI:0914”(association)	0.530
AGMAT	DCX	psi-mi:“MI:0915”(physical association)	0.500
AGMAT	DCX	psi-mi:“MI:0914”(association)	0.500
AGMAT	DLG1	psi-mi:“MI:0407”(direct interaction)	0.440
PDZD7	AGMAT	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	DLG2	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	DLG3	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
LNX2	AGMAT	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	GORASP2	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	MAST2	psi-mi:“MI:0407”(direct interaction)	0.440
PATJ	AGMAT	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	SNTA1	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	HTRA1	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	SNTB1	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	ARHGEF12	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	HTRA4	psi-mi:“MI:0407”(direct interaction)	0.440
MAGI2	AGMAT	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	RADIL	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	ARHGEF11	psi-mi:“MI:0407”(direct interaction)	0.440
AGMAT	TAMALIN	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (49): CLPX (Affinity Capture-MS), RMND5A (Affinity Capture-MS), B3GALNT2 (Affinity Capture-MS), AGMAT (Affinity Capture-MS), BTBD1 (Affinity Capture-MS), AGMAT (Affinity Capture-MS), ACAD9 (Affinity Capture-MS), AGMAT (Affinity Capture-MS), BNIP1 (Affinity Capture-MS), WDR5 (Affinity Capture-MS), AGMAT (Affinity Capture-MS), UGGT2 (Affinity Capture-MS), TRIM56 (Affinity Capture-MS), AGMAT (Two-hybrid), AGMAT (Affinity Capture-MS)

ESM2 similar proteins: A0A193KX02, A1Y9I9, A2AS89, A7YY46, B2RQC6, B6CZ62, B8AU84, E2RDZ6, G7JFU5, H9TB17, H9TB18, H9TB19, O08691, O08701, O49046, P08955, P14012, P27708, P37818, P46637, P55205, Q0D2L3, Q10066, Q17QF0, Q2KHV5, Q2NKY8, Q3UEG6, Q3V1F8, Q3ZBQ0, Q4VK78, Q58DL1, Q5R607, Q5RFA3, Q64565, Q68FX9, Q69ZP3, Q6Q2C2, Q6TL19, Q74ZW4, Q7L2E3

Diamond homologs: A1AFC5, A1KVF9, A2AS89, A4WE75, A6TDU9, A7MJQ1, A7ZR59, A8A477, A8APF8, A8GIX7, A9M254, A9N3R6, B1IT67, B1LDE6, B1XF99, B2U0V8, B4F1A3, B4RP98, B4T5I5, B4THG3, B4TV53, B5BFP3, B5F5K3, B5FUJ0, B5QXK5, B5RE39, B5XUB2, B5YQD4, B6I775, B7LFJ6, B7LPE7, B7LYW6, B7MMC5, B7MZN5, B7N7I9, B7NI01, B7UHY3, C0PY54, C5A0K6, C5BAV1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 96 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Assembly and cell surface presentation of NMDA receptors	8	31.2×	2e-08
Neurexins and neuroligins	10	30.3×	3e-10
Protein-protein interactions at synapses	6	24.5×	2e-05
Non-integrin membrane-ECM interactions	5	11.9×	2e-03
RHOA GTPase cycle	6	6.9×	4e-03
Axon guidance	7	4.9×	8e-03
Neuronal System	7	4.8×	8e-03
Nervous system development	7	4.6×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	8	49.5×	2e-09
protein localization to synapse	6	48.9×	3e-07
receptor clustering	7	46.5×	3e-08
regulation of postsynaptic membrane neurotransmitter receptor levels	6	31.6×	3e-06
cell-cell adhesion	10	10.8×	3e-06
protein-containing complex assembly	6	7.3×	6e-03
chemical synaptic transmission	7	5.8×	7e-03
nervous system development	10	4.9×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	62
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
146292	GRCh38/hg38 1p36.21-36.13(chr1:15052047-16499873)x1	Likely pathogenic
982225	NM_024758.5(AGMAT):c.481G>A (p.Asp161Asn)	Likely pathogenic

SpliceAI

708 predictions. Top by Δscore:

Variant	Effect	Δscore
1:15577679:CCTTA:C	donor_loss	1.0000
1:15577680:CTTAC:C	donor_loss	1.0000
1:15577681:TTA:T	donor_loss	1.0000
1:15577682:TACCT:T	donor_loss	1.0000
1:15577683:A:C	donor_loss	1.0000
1:15577684:CCTGA:C	donor_gain	1.0000
1:15578853:TGTCA:T	donor_loss	1.0000
1:15578854:GTCAC:G	donor_loss	1.0000
1:15578855:TCAC:T	donor_loss	1.0000
1:15578856:CACCT:C	donor_loss	1.0000
1:15578857:A:AT	donor_loss	1.0000
1:15583191:AC:A	donor_gain	1.0000
1:15583192:CC:C	donor_gain	1.0000
1:15583233:ATAGG:A	donor_gain	1.0000
1:15583235:AGG:A	donor_gain	1.0000
1:15584690:CCTTA:C	donor_loss	1.0000
1:15584691:CTTA:C	donor_loss	1.0000
1:15584693:TACC:T	donor_loss	1.0000
1:15584695:C:CT	donor_loss	1.0000
1:15573723:CC:C	acceptor_gain	0.9900
1:15573724:CC:C	acceptor_gain	0.9900
1:15573725:C:CC	acceptor_gain	0.9900
1:15577863:CC:C	acceptor_gain	0.9900
1:15577864:CC:C	acceptor_gain	0.9900
1:15577864:CCTG:C	acceptor_loss	0.9900
1:15577865:C:G	acceptor_loss	0.9900
1:15577866:T:G	acceptor_loss	0.9900
1:15578858:CCTGG:C	donor_gain	0.9900
1:15579050:CATGC:C	acceptor_gain	0.9900
1:15579052:TGC:T	acceptor_gain	0.9900

AlphaMissense

2260 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:15577763:G:C	S274R	0.997
1:15577763:G:T	S274R	0.997
1:15577765:T:G	S274R	0.997
1:15583257:G:C	S137R	0.966
1:15583257:G:T	S137R	0.966
1:15583259:T:G	S137R	0.966
1:15579028:A:T	V184E	0.965
1:15584727:C:G	D81H	0.964
1:15577764:C:A	S274I	0.962
1:15579037:A:G	L181P	0.961
1:15573697:A:G	L338P	0.959
1:15578914:A:T	I222N	0.958
1:15584726:T:A	D81V	0.958
1:15580137:C:G	D161H	0.957
1:15580115:A:T	I168K	0.956
1:15577771:A:C	Y272D	0.951
1:15577859:G:C	F242L	0.949
1:15577859:G:T	F242L	0.949
1:15577861:A:G	F242L	0.949
1:15580136:T:A	D161V	0.944
1:15579023:C:G	A186P	0.942
1:15583375:C:G	R98P	0.937
1:15580115:A:C	I168R	0.936
1:15573706:G:T	A335E	0.934
1:15577761:A:G	F275S	0.931
1:15583390:C:T	G93E	0.929
1:15577726:C:A	G287W	0.927
1:15578911:C:T	G223D	0.924
1:15579024:A:C	D185E	0.924
1:15579024:A:T	D185E	0.924

dbSNP variants (sampled 300 via entrez): RS1000486626 (1:15584340 C>CA), RS1000558085 (1:15581527 T>C), RS1001036171 (1:15573362 G>C), RS1001043178 (1:15581326 G>T), RS1001088608 (1:15573524 C>T), RS1001293945 (1:15576299 T>A), RS1001719027 (1:15584926 C>A,T), RS1001757774 (1:15573118 G>C), RS1002032942 (1:15574594 T>C), RS1002164898 (1:15585117 G>A,C,T), RS1002299569 (1:15574900 C>T), RS1002357157 (1:15574284 A>G), RS1002533530 (1:15580654 G>A,T), RS1002547997 (1:15580930 G>A), RS1002762985 (1:15586162 G>A)

Disease associations

OMIM: gene MIM:617887 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (1): Moyamoya angiopathy (Orphanet:477768)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST004860_117	Alcoholic chronic pancreatitis	3.000000e-08
GCST004860_35	Alcoholic chronic pancreatitis	6.000000e-09
GCST004860_92	Alcoholic chronic pancreatitis	3.000000e-06
GCST007876_63	Estimated glomerular filtration rate	4.000000e-16
GCST008058_57	Estimated glomerular filtration rate	1.000000e-27
GCST008059_64	Estimated glomerular filtration rate	6.000000e-24
GCST008972_155	Urate levels	6.000000e-10
GCST012020_63	Serum metabolite levels	4.000000e-77
GCST90002383_145	Hematocrit	7.000000e-09

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0004348	hematocrit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	2
(+)-JQ1 compound	decreases expression	2
Acetaminophen	decreases expression	2
Valproic Acid	affects expression, decreases expression	2
Cyclosporine	decreases expression	2
Aflatoxin B1	decreases expression, affects expression	2
methylmercuric chloride	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	increases expression	1
nickel sulfate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
K 7174	decreases expression	1
abrine	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	decreases expression	1
Dimethyl Sulfoxide	increases expression	1
Fenfluramine	decreases expression	1
Oxygen	decreases expression	1
Quercetin	decreases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Vanadates	decreases expression	1
Palmitic Acid	decreases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.